Reportedly, the recombinant adenovirus serotype 3-derived protein (JO-1), which triggers the transient opening of intercellular junctions in epithelial tumors by binding to DSG2, enhanced the antitumor activity of several therapeutic monoclonal antibodies in breast cancer, lung cancer, and GC [20]. This evidence concerns the gene DSG2 and lung cancer.